afr, page-9

K
did you see this about Nexavar

Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial)

Results:
Primary TTSP (Time To Symptomatic Progression)analysis demonstrated no statistically significant difference for Sor vs P

and don't forget this bit

Bayer says Nexavar phase III skin cancer tests fail to meet primary endpoint

bayer LEVERKUSEN, Germany (AFX) - Bayer (nyse: BAY ) AG and Onyx Pharmaceuticals Inc said Phase III skin cancer tests of their Nexavar (sorafenib) tablets failed to meet their primary endpoint of improving progression-free survival (PFS).

'We are disappointed, first and foremost, for the patients with refractory metastatic melanoma for whom treatment options are so limited,' Onyx chief executive Hollings Renton said in a statement.